AstraZeneca (AZN) vs Eli Lilly (LLY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Eli Lilly (LLY) has outperformed AstraZeneca (AZN) over the past year, gaining 41.8% versus a loss of 6.5%. Over five years, LLY leads with a +402.8% price change compared with +33.3% for AZN. Eli Lilly is the larger company by market cap ($1.06 trillion vs $248.35 billion), about 4.3 times the size.
On valuation, AstraZeneca trades at a lower forward P/E (13.8x vs 25.0x for Eli Lilly). AstraZeneca offers the higher dividend yield (2.02% vs 0.54%). Eli Lilly converts more of its revenue into profit, with a net margin of 31.7% versus 17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZN | LLY |
|---|---|---|
| Share price | $160.13 | $1,188.29 |
| Market cap | $248.35B | $1.06T |
| 1-day change | +0.96% | +2.66% |
| YTD return | -12.66% | +11.30% |
| 1-year return | -6.49% | +41.78% |
| 5-year return | +33.34% | +402.83% |
| P/E ratio (TTM) | 23.94 | 39.89 |
| Forward P/E | 13.85 | 24.97 |
| EPS (TTM) | $6.69 | $29.79 |
| Dividend yield | 2.02% | 0.54% |
| Annual dividend | $3.23 | $6.46 |
| Revenue (latest FY) | $58.74B | $65.18B |
| Revenue growth (YoY) | +8.63% | +44.70% |
| Net income (latest FY) | $10.22B | $20.64B |
| Gross margin | 81.90% | 83.04% |
| Operating margin | 23.40% | — |
| Net margin | 17.41% | 31.67% |
| 52-week high | $212.71 | $1,292.65 |
| 52-week low | $153.41 | $783.85 |
| Distance from 52-week high | -24.72% | -8.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +31.99% | +11.86% |
| Average volume | 3.41M | 2.48M |
| Shares outstanding | 1.55B | 891.74M |
| Employees | 96,100 | 50,000 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eli Lilly is about 4.3 times larger than AstraZeneca by market value ($1.06T vs $248.35B).
- LLY has outperformed AZN by 48.3 percentage points over the past year.
- Eli Lilly trades at a higher earnings multiple (39.9x vs 23.9x trailing P/E).
- AstraZeneca offers a meaningfully higher dividend yield (2.02% vs 0.54%).
- Eli Lilly is more profitable, keeping 31.7 cents of every revenue dollar as net income versus 17.4 cents for AstraZeneca.
- Eli Lilly grew revenue faster in its latest fiscal year (+44.70% vs +8.63%).
About AstraZeneca
AZN stock →AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Healthcare · Drug Manufacturers - General · 96,100 employees
About Eli Lilly
LLY stock →Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Healthcare · Drug Manufacturers - General · 50,000 employees
AZN vs LLY FAQ
Which is bigger, AstraZeneca or Eli Lilly?
Eli Lilly (LLY) is larger, with a market capitalization of $1.06T compared with $248.35B for AstraZeneca (AZN).
Which stock has performed better over the past year, AZN or LLY?
LLY returned +41.78% over the past 12 months, compared with -6.49% for AZN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AZN or LLY?
AZN has the lower trailing P/E at 23.9, versus 39.9 for LLY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AstraZeneca or Eli Lilly?
AstraZeneca has the higher yield at 2.02%, compared with 0.54% for Eli Lilly.
Are AstraZeneca and Eli Lilly in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.